PHASE™ CMC Transition Service for Alloy Customers

PHASE™ CMC Transition Service for Alloy Customers

CRO

Information

Wheeler’s PHASE™ is a premier service experience offering a seamless transition from discovery to CMC for existing and future ATX-Gx platform users and Alloy Discovery Service partners. PHASE™ integrates the antibody discovery process with our Portable CMC® platform to reduce the timeline from drug candidate selection to initiation of cell line development, resulting in significant risk reduction, increased manufacturing predictability, elimination of the RFP process, and improved knowledge transfer between the CRO and CDMO. Alloy partners that continue with our PHASE™ service also receive economic incentives for the most efficient use of CMC capital. Ultimately, PHASE™ aligns the ecosystem between drug developers, Alloy, and Wheeler to accelerate the translation of drug discoveries to clinical manufacturing. Alloy partners that continue with our PHASE™ service also receive economic incentives for the most efficient use of CMC capital. Ultimately, PHASE™ aligns the ecosystem between drug developers, Alloy, and Wheeler to accelerate the translation of drug discoveries to clinical manufacturing. With PHASE™, Alloy customers contracting Wheeler Portable CMC® Lead to Tox or Lead to Clinic services benefit from: • Dollar-for-dollar reductions in Alloy commercial milestones for Wheeler services contracted • Free CMC consulting to guide you from discovery to CMC development • Zero-charge CHO pool generation for up to 4 leads Additionally, Alloy customers contracting Wheeler Portable CMC® Lead to Clinic programs benefit from: • A 50% reduction in the Wheeler initial payment • Zero reservation fee required to hold manufacturing slots • This strategic integrated offering promises to significantly reduce risk, increase predictability, and boost your journey from discovery to successful clinical development, ultimately advancing your drug programs into the hands of patients more rapidly than ever before.
Wheeler Bio832Wheeler Bio is a biomanufacturing pioneer founded by a team of industry experts and strategic investors who believe a different CDMO model is needed for innovators to bring new therapeutic leads to the clinic faster, without the risk and cost associated with traditional outsourcing models. Our novel hub-and-spoke concept, centered in Oklahoma City with satellite labs embedded in discovery centers on the coasts, will revolutionize the translational path from discovery to CMC development and first patient dosing. Wheeler’s pioneering, highly-accessible, open-source development platform – Portable CMC® – delivers speed to clinic and uniquely-affordable workflows by integrating discovery CROs and CDMOs. Portable CMC® is a suite-ready drug substance manufacturing platform that customers can transfer to any CDMO in the world with no royalties, licensing fees or penalties. By overlapping with the discovery workflow, Portable CMC® reduces timelines and regulatory risks through the introduction of QbD (Quality-by-Design) principles earlier on in the drug development life cycle, increasing the opportunity for clinical success.

Log in